LIMN Liminatus Pharma (NASDAQ) pre-market +15% Feb 12 2026: earnings preview
LIMN stock jumps +15.08% pre-market on Feb 12, 2026 ahead of an earnings announcement that could reshape sentiment for Liminatus Pharma, Inc. Class A Common Stock (LIMN) on the NASDAQ. The market priced shares at $1.45 USD with heavy activity: 75,679,723 shares traded versus an average of 6,819,985.00. Investors will watch clinical updates and cash runway notes closely because the company is a clinical-stage biotechnology name with negative EPS -0.16 and thin liquidity.
Continue Reading on Meyka
This article is available in full on our main platform. Get access to complete analysis, stock insights, and more.
Read Full Article →
